2m 2m 2m 2m 2m 2m 2m
- $94.8MMarket Cap
- 68.59%1-Year Change
- BiotechnologyIndustry
Immucell (ICCC)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 91
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
ImmuCell Q2 Profit Jumps as Margins Rise
ImmuCell reported Q2 2025 results with improved gross margins and completed First Defense production capacity expansion, but faces ongoing FDA approval delays for Retain product, creating uncertainty in near-term growth trajectory.
08/15/2025, 10:01 AM • The Motley Fool
Peers
Statistics
MoreInformation as of 10/23/2026
Company Profile
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.
Key Executives
- Bobbi Jo Brockmann
- Timothy C. Fiori
- Paul F. Olivier Te Boekhorst
- Elizabeth S. Toothaker
- John W. Zinckgraf
Current Ownership Distribution
- Institutions21.0M (72.41%)
- Mutual Funds6.7M (23.28%)
- Insiders1.2M (4.30%)
- Other0 (0.00%)